Program

1 Oct
2 Oct

1 Oct
Time	Session
19:00 – 21:00	Networking Event ZIBO 90 rue Peel, Montréal Québec Complimentary wine and a light dinner

2 Oct
Time	Session
8:00 – 9:00	Light Breakfast Available in the Foyer
8:30 – 8:45	Welcome/Opening remarks Jane Aubin, Chief Scientific Officer, Vice-President of Research CIHR
8:45 – 9:00	Overview and Purpose of the Workshop Cara Tannenbaum, Scientific director, CIHR Institute of Gender and Health
9:00 – 9:45	Roundtable 1: What is known about the effect of sex on drug-gene interactions at the molecular/cellular level? Pharmacogenomics, sex hormones and cancer progression Chantal Guillemette Professor, Université Laval Mechanisms of drug-gene interactions for cardiovascular therapies Jean-Claude Tardif Montreal Heart Institute Clinical trials, genes and sex Marie-Pierre Dubé
9:30 – 10:15	Discussion Biomedical and translational research on sex-drug-gene interactions: what are the trends, gaps, and barriers? Does Canada have the capacity to be a leader in this space? Facilitated by Paul Lasko, Scientific Director, Institute of Genetics
10:30 – 10:45	Break
10:45 – 11:30	Roundtable 2: Clinical Practice Interventions to Prevent Sex-Drug-Gene Interactions Primary Care Pharmacogenomics: Avoiding alert fatigue Martin Dawes Royal Canadian Legion Professor and Head, Family Practice, University of British Columbia Applications of sex differences in drug disposition to in the emerging field of Personalized Medicine Richard Kim Professor, Medicine, University of Western Ontario Response to chemotherapy – genes, gender and gaps Rod Rassekh Pediatrics (Division of Peds Heme/Onc/BMT), University of British Columbia Moderated by Paul Lasko, Scientific Director, Institute of Genetics
11:30 – 12:15	Discussion How can we better deliver care in clinical practice? Should personalized medicine be paying more attention to age, sex and gender? Does Canada have the capacity to be a leader in this space? Facilitated by Steve Robbins, Scientific Director, Institute of Genetics
12:15 – 13:00	Lunch
13:00 – 13:45	Roundtable 3: Health System Change - Looking towards the future Transforming the clinical use of drugs with pharmacogenomics Bruce Carleton Director, Pharmaceutical Outcomes Programme, Pediatrics, The University of British Columbia Challenges in the Clinical Translation of Molecular Diagnostics Katherine Bonter Director of Intellectual Property, MHI; Director of Commercialisation, PCITP, Montreal Heart Institute; Hopital Maisoneuve Rosemont Insights from someone who worked in government over the past decade Robert Peterson Moderated by Cara Tannenbaum, Scientific Director, Institute of Gender & Health
14:30 – 15:30	Break-out Sessions What are the research priorities? Where can Canada show innovation and leadership in this space?
15:30 – 16:00	Report Back (10min/group)
16:00 – 16:30	Wrap up and Next Steps All Scientific Directors